Clinical Trial Update: Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial [Phase 3]

View source ↗

Summary

The INNOVATE Phase 3 trial is evaluating adding apalutamide to standard hormone therapy and radiation after prostate cancer surgery and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)

Snippet

Sponsor: NRG Oncology | Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8 | Phase 3 | Status: RECRUITING